Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (301) 301
Newspaper Article (112) 112
Patent (94) 94
Publication (45) 45
Book Review (17) 17
Magazine Article (15) 15
Book / eBook (7) 7
Dissertation (2) 2
Book Chapter (1) 1
Technical Report (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (131) 131
chemistry (90) 90
metallurgy (90) 90
organic chemistry (68) 68
human necessities (62) 62
peptides (60) 60
index medicus (57) 57
hygiene (54) 54
medical or veterinary science (54) 54
preparations for medical, dental, or toilet purposes (54) 54
oncology (44) 44
biochemistry (42) 42
beer (41) 41
enzymology (41) 41
microbiology (41) 41
mutation or genetic engineering (41) 41
spirits (41) 41
vinegar (41) 41
wine (41) 41
physics (40) 40
female (39) 39
hematology (39) 39
investigating or analysing materials by determining theirchemical or physical properties (39) 39
measuring (39) 39
testing (39) 39
male (37) 37
compositions thereof (33) 33
culture media (33) 33
microorganisms or enzymes (33) 33
middle aged (33) 33
propagating, preserving or maintaining microorganisms (33) 33
adult (31) 31
expression (30) 30
lymphoma, large b-cell, diffuse - genetics (28) 28
animals (25) 25
cancer (25) 25
aged (23) 23
lymphoma, large b-cell, diffuse - pathology (23) 23
article (22) 22
lymphomas (21) 21
gene-expression (20) 20
hemic and lymphatic diseases (19) 19
cell biology (18) 18
cell line, tumor (18) 18
lymphoma (18) 18
chemical composition of glasses, glazes, or vitreousenamels (17) 17
glass (17) 17
joining glass to glass or other materials (17) 17
mice (17) 17
mineral or slag wool (17) 17
surface treatment of fibres or filaments made from glass,minerals or slags (17) 17
surface treatment of glass (17) 17
activation (16) 16
apoptosis (16) 16
gene expression regulation, neoplastic (16) 16
abridged index medicus (15) 15
compositions or test papers therefor (15) 15
condition-responsive control in microbiological orenzymological processes (15) 15
gene expression profiling (15) 15
lymphoma, large b-cell, diffuse - metabolism (15) 15
measuring or testing processes involving enzymes, nucleicacids or microorganisms (15) 15
molecular sequence data (15) 15
processes of preparing such compositions (15) 15
prognosis (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
biochemistry & molecular biology (14) 14
immunohistochemistry (14) 14
lymphoma, b-cell - pathology (14) 14
treatment outcome (14) 14
enzymes (13) 13
lymphoma, b-cell - genetics (13) 13
gene (12) 12
general tagging of cross-sectional technologies spanning over several sections of the ipc (12) 12
general tagging of new technological developments (12) 12
technical subjects covered by former uspc (12) 12
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (12) 12
b-cell lymphoma (11) 11
cell line (11) 11
gene expression (11) 11
hodgkin lymphoma (11) 11
research (11) 11
tumors (11) 11
amino acid sequence (10) 10
base sequence (10) 10
chemotherapy (10) 10
genes (10) 10
hodgkin disease - genetics (10) 10
immunology (10) 10
lymphoma, large b-cell, diffuse - drug therapy (10) 10
multidisciplinary sciences (10) 10
therapy (10) 10
antineoplastic agents - therapeutic use (9) 9
cyclophosphamide - administration & dosage (9) 9
heterocyclic compounds (9) 9
hodgkin disease - pathology (9) 9
immune system diseases (9) 9
mutation (9) 9
neoplasm proteins - genetics (9) 9
proteins (9) 9
reed-sternberg cells (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Abstract IA6: Immune escape mechanisms in lymphoid malignancies
by Shipp, Margaret A
Cancer Research, ISSN 0008-5472, 01/2013, Volume 73, Issue 1 Supplement, pp. IA6 - IA6
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Abstract IA38: Identification of targetable vulnerabilities in lymphoma
by Shipp, Margaret
Clinical Cancer Research, ISSN 1078-0432, 09/2015, Volume 21, Issue 17 Supplement, pp. IA38 - IA38
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Reply to Z. Wu et Al
by Neuberg, Donna S and Rodig, Scott J and Shipp, Margaret A
Journal of Clinical Oncology, ISSN 0732-183X, 09/2018, Volume 36, Issue 25, pp. 2657 - 2657
HLA Antigens | B7-H1 Antigen | Hodgkin Disease | Humans
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma
by Liu, W Robert and Shipp, Margaret A
Blood, ISSN 0006-4971, 11/2017, Volume 130, Issue 21, pp. 2265 - 2270
Classical Hodgkin lymphoma (cHL) is an unusual B-cell-derived malignancy in which rare malignant Hodgkin and Reed-Sternberg (HRS) cells are surrounded by an... 
B7-H1 Antigen - metabolism | Reed-Sternberg Cells - pathology | Hodgkin Disease - metabolism | Signal Transduction | Hodgkin Disease - genetics | Humans | Hodgkin Disease - diagnosis | Immune Evasion - genetics | Tumor Microenvironment | Hodgkin Disease - immunology | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
by Ansell, Stephen M and Lesokhin, Alexander M and Borrello, Ivan and Halwani, Ahmad and Scott, Emma C and Gutierrez, Martin and Schuster, Stephen J and Millenson, Michael M and Cattry, Deepika and Freeman, Gordon J and Rodig, Scott J and Chapuy, Bjoern and Ligon, Azra H and Zhu, Lili and Grosso, Joseph F and Kim, Su Young and Timmerman, John M and Shipp, Margaret A and Armand, Philippe
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 4, pp. 311 - 319
In a small series of patients with refractory Hodgkin's lymphoma, a substantial rate of tumor regression (87%) was documented in response to blockade of the... 
THERAPEUTICS | MEDICINE, GENERAL & INTERNAL | ANTI-PD-1 ANTIBODY | RESPONSE CRITERIA | SAFETY | PHASE-II | PIDILIZUMAB | STEM-CELL TRANSPLANTATION | LYMPHOPROLIFERATIVE DISORDERS | CANCER | T-CELLS | Recurrence | Hodgkin Disease - metabolism | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | STAT Transcription Factors - metabolism | Programmed Cell Death 1 Ligand 2 Protein - metabolism | Programmed Cell Death 1 Receptor - metabolism | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Janus Kinases - metabolism | Antineoplastic Agents - administration & dosage | Stem Cell Transplantation | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Hodgkin Disease - therapy | Immunotherapy | Hodgkin Disease - drug therapy | Immunoconjugates - therapeutic use | Adult | Female | Reed-Sternberg Cells - drug effects | Medical research | Autografts | Transplants & implants | Transcription | PD-1 protein | Toxicity | Body weight | Blocking antibodies | Stat3 protein | Stem cell transplantation | Lymphoma | Chromosome 9 | PD-L1 protein | Tomography | PD-L2 protein | Janus kinase | Ligands | Lymphomas | Drug therapy | Hodgkin's disease | Cancer | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma
by Liu, W. Robert and Shipp, Margaret A
Blood, ISSN 0006-4971, 11/2017, Volume 130, Issue 21, pp. 2265 - 2270
Classical Hodgkin lymphoma (cHL) is an unusual B-cell-derived malignancy in which rare malignant Hodgkin and Reed-Sternberg (HRS) cells are surrounded by an... 
REED-STERNBERG CELLS | ACTIVATION | INHIBITION | PD-1 BLOCKADE | TUMOR-SUPPRESSOR GENE | REGULATORY T-CELLS | CENTRAL-NERVOUS-SYSTEM | NIVOLUMAB | HEMATOLOGY | NF-KAPPA-B | EXPRESSION
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure
by Armand, Philippe and Shipp, Margaret A and Ribrag, Vincent and Michot, Jean-Marie and Zinzani, Pier Luigi and Kuruvilla, John and Snyder, Ellen S and Ricart, Alejandro D and Balakumaran, Arun and Rose, Shelonitda and Moskowitz, Craig H
Journal of Clinical Oncology, ISSN 0732-183X, 11/2016, Volume 34, Issue 31, pp. 3733 - 3739
Purpose Classical Hodgkin lymphoma (HL) frequently exhibits genetic alterations leading to overexpression of the programmed death-1 (PD-1) ligands, suggesting... 
TRIAL | INTERFERON | ONCOLOGY | SAFETY | TOLERANCE | ANTIBODY | PIDILIZUMAB | STEM-CELL TRANSPLANTATION | CANCER | PD-1 | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Hodgkin Disease - metabolism | Humans | Middle Aged | Programmed Cell Death 1 Receptor - metabolism | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Remission Induction | Young Adult | Disease-Free Survival | Antineoplastic Agents, Immunological - adverse effects | B7-H1 Antigen - metabolism | Antineoplastic Agents, Immunological - therapeutic use | Treatment Failure | Hodgkin Disease - drug therapy | Immunoconjugates - therapeutic use | Adult | Female | Aged | Cohort Studies | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma
by Liu, W. Robert and Shipp, Margaret A
Hematology, ISSN 1520-4391, 12/2017, Volume 2017, Issue 1, pp. 310 - 316
Classical Hodgkin lymphoma (cHL) is an unusual B-cell-derived malignancy in which rare malignant Hodgkin and Reed-Sternberg (HRS) cells are surrounded by an... 
Tumor Escape - drug effects | Chromosomes, Human, Pair 9 - immunology | Tumor Escape - genetics | Hodgkin Disease - genetics | Hodgkin Disease - pathology | Humans | Neoplasm Proteins - immunology | Signal Transduction - genetics | Tumor Microenvironment - immunology | Chromosomes, Human, Pair 9 - genetics | Tumor Microenvironment - genetics | Hodgkin Disease - immunology | Neoplasm Proteins - genetics | New Insights and New Approaches | Hodgkin Lymphoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin Lymphoma
by Chen, Robert and Zinzani, Pier Luigi and Fanale, Michelle A and Armand, Philippe and Johnson, Nathalie A and Brice, Pauline and Radford, John and Ribrag, Vincent and Molin, Daniel and Vassilakopoulos, Theodoros P and Tomita, Akihiro and Von Tresckow, Bastian and Shipp, Margaret A and Zhang, Yinghua and Ricart, Alejandro D and Balakumaran, Arun and Moskowitz, Craig H and KEYNOTE-087 Investigators and KEYNOTE-087 and for the KEYNOTE-087 and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Institutionen för immunologi, genetik och patologi and Uppsala universitet and Experimentell och klinisk onkologi
Journal of Clinical Oncology, ISSN 0732-183X, 07/2017, Volume 35, Issue 19, pp. 2125 - 2132
Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2.... 
TRIAL | THERAPY | ONCOLOGY | BIOLOGY | BRENTUXIMAB VEDOTIN | PD-L1 | STEM-CELL TRANSPLANTATION | FAILURE | Antibodies, Monoclonal, Humanized - adverse effects | Recurrence | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Young Adult | Antineoplastic Agents - adverse effects | Hodgkin Disease - drug therapy | Adult | Female | Aged | Cohort Studies | Life Sciences | Cancer | ORIGINAL REPORTS | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Mass cytometry of Hodgkin lymphoma reveals a CD41 regulatory T-cell–rich and exhausted T-effector microenvironment
by Cader, Fathima Zumla and Schackmann, Ron C. J and Hu, Xihao and Wienand, Kirsty and Redd, Robert and Chapuy, Bjoern and Ouyang, Jing and Paul, Nicole and Gjini, Evisa and Lipschitz, Mikel and Armand, Philippe and Wu, David and Fromm, Jonathan R and Neuberg, Donna and Shirley Liu, X and Rodig, Scott J and Shipp, Margaret A
Blood, ISSN 0006-4971, 08/2018, Volume 132, Issue 8, pp. 825 - 836
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma
by Nayak, Lakshmi and Iwamoto, Fabio M and Lacasce, Ann and Mukundan, Srinivasan and Roemer, Margaretha G.M and Chapuy, Bjoern and Armand, Philippe and Rodig, Scott J and Shipp, Margaret A
Blood, ISSN 0006-4971, 06/2017, Volume 129, Issue 23, pp. 3071 - 3073
Primary central nervous system (CNS) lymphoma (PCNSL) and primary testicular lymphoma (PTL) are rare extranodal large B-cell lymphomas with similar genetic... 
PRIMARY CNS LYMPHOMA | WHOLE-BRAIN RADIATION | DIAGNOSIS | SINGLE | IMMUNOCOMPETENT PATIENTS | CLASSICAL HODGKIN LYMPHOMA | STEM-CELL TRANSPLANTATION | HEMATOLOGY | FAILURE | FEATURES | Testicular Neoplasms - therapy | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Neoplasm Recurrence, Local - therapy | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Central Nervous System Neoplasms - therapy | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Tomography, X-Ray Computed | Treatment Outcome | Antineoplastic Agents - therapeutic use | Testicular Neoplasms - diagnostic imaging | Neoplasm Recurrence, Local - diagnostic imaging | Antineoplastic Agents - adverse effects | Central Nervous System Neoplasms - diagnostic imaging | Aged, 80 and over | Aged | Lymphoma, B-Cell - diagnostic imaging | Programmed Cell Death 1 Receptor - immunology | Clinical Trials and Observations | Brief Report
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors
by Croci, Diego O and Cerliani, Juan P and Dalotto-Moreno, Tomas and Méndez-Huergo, Santiago P and Mascanfroni, Ivan D and Dergan-Dylon, Sebastián and Toscano, Marta A and Caramelo, Julio J and García-Vallejo, Juan J and Ouyang, Jing and Mesri, Enrique A and Junttila, Melissa R and Bais, Carlos and Shipp, Margaret A and Salatino, Mariana and Rabinovich, Gabriel A
Cell, ISSN 0092-8674, 02/2014, Volume 156, Issue 4, pp. 744 - 758
The clinical benefit conferred by vascular endothelial growth factors (VEGF)-targeted therapies is variable, and tumors from treated patients eventually... 
GALECTIN-1 | ACTIVATION | THERAPY | BIOCHEMISTRY & MOLECULAR BIOLOGY | IMMUNE PRIVILEGE | INHIBITS GROWTH | DISEASE | RESISTANCE | MECHANISMS | HUMAN ENDOTHELIAL-CELLS | PROGRESSION | CELL BIOLOGY | Endothelial Cells - metabolism | Vascular Endothelial Growth Factors - antagonists & inhibitors | Humans | Neovascularization, Pathologic | Galectin 1 - genetics | Galectin 1 - metabolism | Neoplasms - blood supply | Receptors, Mitogen - metabolism | Glycosylation | Neoplasms - drug therapy | Animals | Angiogenesis Inhibitors - therapeutic use | Hypoxia | Mice | Medical colleges | Polysaccharides | Endothelial growth factors | Lectins | Cells | Organic acids | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Constitutive AP-1 activity and EBV infection induce PD-l1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy
by Green, Michael R and Rodig, Scott and Juszczynski, Przemyslaw and Ouyang, Jing and Sinha, Papiya and O'Donnell, Evan and Neuberg, Donna and Shipp, Margaret A
Clinical Cancer Research, ISSN 1078-0432, 03/2012, Volume 18, Issue 6, pp. 1611 - 1618
Purpose: Programmed cell death ligand 1 (PD-L1) is a molecule expressed on antigen-presenting cells that engages the PD-1 receptor on T cells and inhibits... 
PATHOGENESIS | ONCOLOGY | CLASSICAL HODGKIN | COSTIMULATORY MOLECULE | C-JUN | EXPRESSION | EPSTEIN-BARR-VIRUS | LIGAND 1 | CD8 T-CELLS | LATENT MEMBRANE PROTEIN-1 | CLINICAL-SIGNIFICANCE | Hodgkin Disease - virology | Hodgkin Disease - genetics | Transcription Factor AP-1 - genetics | Humans | Lymphoproliferative Disorders - genetics | Chromosomes, Human, Pair 9 | Viral Matrix Proteins - pharmacology | B7-H1 Antigen - metabolism | Immunosuppression | Enhancer Elements, Genetic | Cell Line, Tumor | Cell Transformation, Viral - genetics | Epstein-Barr Virus Infections - complications | Hodgkin Disease - immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma
by Croci, Diego O and Salatino, Mariana and Rubinstein, Natalia and Cerliani, Juan P and Cavallin, Lucas E and Leung, Howard J and Ouyang, Jing and Ilarregui, Juan M and Toscano, Marta A and Domaica, Carolina I and Croci, María C and Shipp, Margaret A and Mesri, Enrique A and Albini, Adriana and Rabinovich, Gabriel A
Journal of Experimental Medicine, ISSN 0022-1007, 10/2012, Volume 209, Issue 11, pp. 1985 - 2000
Kaposi's sarcoma (KS), a multifocal vascular neoplasm linked to human herpesvirus-8 (HHV-8/KS-associated herpesvirus [KSHV]) infection, is the most common... 
MEDICINE, RESEARCH & EXPERIMENTAL | T-CELL APOPTOSIS | TUMOR-IMMUNE PRIVILEGE | PARACRINE NEOPLASIA | CANCER CELLS | PROTEIN-COUPLED RECEPTOR | KSHV | ENDOTHELIAL-CELLS | GENE-EXPRESSION | HERPESVIRUS VGPCR | INDUCTION | IMMUNOLOGY | Galectin 1 - immunology | Sarcoma, Kaposi - metabolism | Humans | Gene Expression Regulation, Neoplastic | Galectin 1 - genetics | Galectin 1 - metabolism | Immunoblotting | Sarcoma, Kaposi - drug therapy | Cell Hypoxia | RNA Interference | Protein Binding - drug effects | HEK293 Cells | Neovascularization, Pathologic - prevention & control | Herpesvirus 8, Human - physiology | Antibodies, Monoclonal - pharmacology | Mice, Inbred C57BL | Cells, Cultured | Antibodies, Neutralizing - pharmacology | Reverse Transcriptase Polymerase Chain Reaction | Mice, Knockout | Polysaccharides - metabolism | Host-Pathogen Interactions | Xenograft Model Antitumor Assays | Animals | Mice, Nude | Cell Line, Tumor | Hypoxia | Neovascularization, Pathologic - genetics | Mice | Neovascularization, Pathologic - metabolism | Sarcoma, Kaposi - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
by Chapuy, Bjoern and McKeown, Michael R and Lin, Charles Y and Monti, Stefano and Roemer, Margaretha G.M and Qi, Jun and Rahl, Peter B and Sun, Heather H and Yeda, Kelly T and Doench, John G and Reichert, Elaine and Kung, Andrew L and Rodig, Scott J and Young, Richard A and Shipp, Margaret A and Bradner, James E
Cancer Cell, ISSN 1535-6108, 12/2013, Volume 24, Issue 6, pp. 777 - 790
Diffuse large B cell lymphoma (DLBCL) is a biologically heterogeneous and clinically aggressive disease. Here, we explore the role of bromodomain and... 
SELECTIVE-INHIBITION | CHROMATIN | ONCOLOGY | TRANSCRIPTION | GENE-EXPRESSION | C-MYC | OCA-B | LEUKEMIA | BET BROMODOMAIN INHIBITION | P-TEFB | BRD4 | CELL BIOLOGY | Promoter Regions, Genetic | Humans | Genes, myc | Transcription Factors - genetics | DNA-Binding Proteins - genetics | Trans-Activators - physiology | Azepines - pharmacology | Triazoles - pharmacology | Enhancer Elements, Genetic | Transcription, Genetic | Nuclear Proteins - genetics | Lymphoma, Large B-Cell, Diffuse - genetics | Proto-Oncogene Proteins c-bcl-6 | Proteins | Lymphomas | Biochemical genetics | Genomics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study
by Lesokhin, Alexander M and Ansell, Stephen M and Armand, Philippe and Scott, Emma C and Halwani, Ahmad and Gutierrez, Martin and Millenson, Michael M and Cohen, Adam D and Schuster, Stephen J and Lebovic, Daniel and Dhodapkar, Madhav and Avigan, David and Chapuy, Bjoern and Ligon, Azra H and Freeman, Gordon J and Rodig, Scott J and Cattry, Deepika and Zhu, Lili and Grosso, Joseph F and Brigid Bradley Garelik, M and Shipp, Margaret A and Borrello, Ivan and Timmerman, John
Journal of Clinical Oncology, ISSN 0732-183X, 08/2016, Volume 34, Issue 23, pp. 2698 - 2704
Purpose Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway to avoid immune surveillance by modulating T-lymphocyte activity. In... 
MULTIPLE-MYELOMA | B-CELL LYMPHOMA | B7-H1 PD-L1 | RESPONSE CRITERIA | ONCOLOGY | ADVANCED MELANOMA | ANTIBODY | BLOCKADE | EXPRESSION | CANCER | IPILIMUMAB | T-Lymphocytes - physiology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Ligand 2 Protein - metabolism | Male | Antineoplastic Agents - administration & dosage | Lymphoma, B-Cell - genetics | Young Adult | Mycosis Fungoides - pathology | Multiple Myeloma - drug therapy | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | T-Lymphocytes - drug effects | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Mycosis Fungoides - genetics | Lymphoma, B-Cell - drug therapy | Programmed Cell Death 1 Ligand 2 Protein - genetics | Treatment Outcome | Chromosomes, Human, Pair 9 | Lymphoma, T-Cell - genetics | B7-H1 Antigen - genetics | Mycosis Fungoides - drug therapy | Retreatment | B7-H1 Antigen - metabolism | Lymphoma, T-Cell - drug therapy | Multiple Myeloma - pathology | Antibodies, Monoclonal - administration & dosage | Lymphocyte Activation - drug effects | Chromosome Aberrations | Lymphoma, B-Cell - pathology | Lymphoma, T-Cell - pathology | Aged | Biomarkers, Tumor - genetics | Cell Proliferation - drug effects | Multiple Myeloma - genetics | ORIGINAL REPORTS | Pedi11
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma
by Zinzani, Pier Luigi and Ribrag, Vincent and Moskowitz, Craig H and Michot, Jean-Marie and Kuruvilla, John and Balakumaran, Arun and Zhang, Yayan and Chlosta, Sabine and Shipp, Margaret A and Armand, Philippe
Blood, ISSN 0006-4971, 07/2017, Volume 130, Issue 3, pp. 267 - 270
Treatment options for relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) are limited, and prognosis is generally poor (overall response... 
DIAGNOSIS | BRENTUXIMAB VEDOTIN | HODGKIN LYMPHOMA | JAK2 | HEMATOLOGY | EXPRESSION | CHEMOTHERAPY | Mediastinal Neoplasms - genetics | Prognosis | Humans | Neoplasm Recurrence, Local - drug therapy | Male | Mediastinal Neoplasms - mortality | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Neoplasm Recurrence, Local - mortality | Mediastinal Neoplasms - drug therapy | Patient Safety | Adult | Female | Gene Expression | Antibodies, Monoclonal, Humanized - therapeutic use | Lymphoma, Large B-Cell, Diffuse - drug therapy | Drug Administration Schedule | Programmed Cell Death 1 Receptor - metabolism | Treatment Outcome | Neoplasm Recurrence, Local - diagnosis | Mediastinal Neoplasms - diagnosis | Lymphoma, Large B-Cell, Diffuse - mortality | Lymphoma, Large B-Cell, Diffuse - diagnosis | Survival Analysis | Neoplasm Recurrence, Local - genetics | Lymphoma, Large B-Cell, Diffuse - genetics | Programmed Cell Death 1 Receptor - genetics | Life Sciences | Cancer | Clinical Trials and Observations | Brief Report
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights